TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03089775
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Comparator
Study: NCT00362934
Drug: fenofibrate / simvastatin
Normalized name: fenofibrate / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fenofibrate and simvastatin 20 mg and 40 mg
Study: NCT00471705
Drug: Glucantime®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
Study: NCT00485771
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000430
Drug: Estrogen/progestin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01196260
Drug: Capecitabine and Oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine and Oxaliplatin will be under the NSCLC guideline
Study: NCT03735030
Drug: Human hCG 10'000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.
Study: NCT01826110
Drug: [11C]PIB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 15 mCI \[11C\]PIB IV x1
Study: NCT03496623
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT03065660
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be an oral tablet in the same form as the IMP, and identical in appearance.
Study: NCT04452474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
Study: NCT04130802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle eye drops
Study: NCT01384292
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg oral tablet once daily
Study: NCT01384292
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral tablet once daily
Study: NCT01384292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment
Study: NCT02266433
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders.
Study: NCT03987087
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy
Study: NCT03324360
Drug: Hyperpolarized 13C-Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI with Hyperpolarized 13C-Pyruvate Injection
Study: NCT03260569
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.
Study: NCT01469559
Drug: Novolin Toronto insulin
Normalized name: insulin isophane / insulin, regular, human Injectable Suspension [Novolin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.
Study: NCT00603616
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo pills to be taken twice daily for a total of 8 weeks
Study: NCT01022632
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
Study: NCT03408483
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
Study: NCT00448019
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m\^2 IV over 30 minutes daily for 3 days
Study: NCT00002905
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002905
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03128905
Drug: Colchicine opocalcium 1mg
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: International non-proprietary name: Colchicine~Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.~Composition :~Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesium stearate and povidone.
Study: NCT00798447
Drug: MLF 541
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
Study: NCT03086473
Drug: Caffeine Citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention in this study is timing of the initial caffeine dose. In the Caffeine arm, participants will receive Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) within 2 hours of life, and Normal Saline (0.9% NaCl) 1ml/kg IV at 12 hours of life.
Study: NCT03146000
Drug: meloxicam rectal suppository
Normalized name: meloxicam Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: suppository
Study: NCT03247920
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic therapy following local protocol
Study: NCT00585000
Drug: CP-675,206
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
Study: NCT03173391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID Oral administration
Study: NCT01748279
Drug: Lactose tablet
Normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One lactose tablet taken once a day as add-on treatment to Formoterol therapy
Study: NCT03962686
Drug: statin Oral Tablet plus PCSK9i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the third study cohort will receive for statin oral therapy plus 140 mg twice a month PCSK9i therapy via subcutaneous injection before to practice surgical intervention for carotid artery obstruction.
Study: NCT00239616
Drug: iron sucrose injection USP
Normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00111280
Drug: TMC125
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03228355
Drug: Levcromakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: To investigate the role of Levcromakalim on cerebral hemodynamic in migraine patients
Study: NCT05040828
Drug: No oral drug therapy throughout the pollen period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Study: NCT03741114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received 100 ml saline just before skin incision
Study: NCT01053390
Drug: epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01147744
Drug: GSK2190915 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 100mg (1 x 100mg) once daily in the morning
Study: NCT01147744
Drug: GSK2190915 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 10mg (1 x 10mg) once daily in the morning
Study: NCT01147744
Drug: GSK2190915 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
Study: NCT01147744
Drug: GSK2190915 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 30mg (1 x 30mg) once daily in the morning
Study: NCT01147744
Drug: Placebo GSK2190915 one tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, one tablet once daily in the morning
Study: NCT01314417
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 μg/100 μL monthly injections for the first 3 months, then as needed per the treatment criteria
Study: NCT04627038
Drug: LY3556050
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3556050 Given orally
Study: NCT04627038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Given orally
Study: NCT01147744
Drug: Placebo GSK2190915 two tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, two tablets once daily in the morning
Study: NCT01641900
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
Study: NCT00199056
Drug: Dexamethasone / Prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00199056
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00199056
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02073175
Drug: Motherwell
Approvals — FDA: no, EMA: no, PMDA: no
Description: The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
Study: NCT01585272
Drug: ENA713
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00941174
Drug: 13C5-Calcium-L-Leucovorin
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
Study: NCT02986503
Drug: Doxorubicin+cisplatin+ifosfamide
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy for Good responder high grade osteosarcoma
Study: NCT02986503
Drug: Doxorubicin+cisplatin+ifosfamide+methotrexate
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy for Poor responder high grade osteosarcoma
Study: NCT03596944
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed with statins for primary prevention
Study: NCT01173692
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
Study: NCT01173692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
Study: NCT03967223
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be used as the lymphodepleting chemotherapy.
Study: NCT00850174
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg Tablet
Study: NCT00850174
Drug: Trileptal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Tablet
Study: NCT01333332
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine
Study: NCT02363803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline, approved for hypovolemia, and homeostasis.
Study: NCT03092232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for PF-06865571 for each cohort.
Study: NCT04146883
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin
Study: NCT00578552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill - non active sugar pill designed to look alike to the gabapentin medication
Study: NCT03575403
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo capsules.
Study: NCT04128995
Drug: Advanced Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes
Study: NCT04202679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study: NCT04202679
Drug: Moisturizers
Normalized name: SPF 8 Lip Moisturizers KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:~Route of administration: Topical
Study: NCT04202679
Drug: Topical calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:~Route of administration: Topical
Study: NCT01982318
Drug: VitroGro® ECM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01982318
Drug: Dulbecco's Phosphate Buffered Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00489307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PO twice daily x 14 days
Study: NCT01629381
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg os once daily for 1 week
Study: NCT02169115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, s.c., every 4 weeks
Study: NCT01534520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: KY Jelly
Study: NCT00868348
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
Study: NCT01186471
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo - three times daily during each treatment period
Study: NCT04066023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm\^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
Study: NCT04362007
Drug: ASTX660
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of ASTX660 for r/r ATLL
Study: NCT05468060
Drug: PA1010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as control
Study: NCT03097107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks
Study: NCT03018834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
Study: NCT04107675
Drug: Liposomal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal Placebo is administered with the same new technology of nebulizing liquid drugs used for L-CsA, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Study: NCT00857389
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
Study: NCT01552694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, matching placebo daily for 2 months
Study: NCT01965522
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
Study: NCT01965522
Drug: Placebo (melatonin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
Study: NCT01965522
Drug: Placebo (vitamin D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
Study: NCT00749645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 30mg tabs, 3/day, 105 days continuously.
Study: NCT04456296
Drug: Aveed Injectable Product
Normalized name: Aveed Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone undecanoate administered by intramuscular injections.
Study: NCT02004119
Drug: KHK4577
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02004119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01766128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The second arm will receive placebo
Study: NCT00904800
Drug: AZD0837
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, oral, once daily, 1+5 days
Study: NCT00904800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00857389
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
Study: NCT00356850
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01469559
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo are provided with 1.1 milliliters of normal saline at randomization (week 5). The study completes at week 11. The total treatment period is 6 weeks. The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast)and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. The amount of normal saline in the study treatment vial (1.1 milliliters) is identical in volume to the active insulin being used in the study .
Study: NCT03668509
Drug: SHR1459
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral adminstration, single dose
Study: NCT01790503
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02681679
Drug: 0.1% bromfenac ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00359905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for 12 weeks
Study: NCT00683163
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg by mouth once monthly
Study: NCT00374803
Drug: Mycophenolic Acid (Myfortic)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~* Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).
Study: NCT01027611
Drug: proparacaine HCL 0.5%
Normalized name: PROPARACAINE HCL 0.5% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01235559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses, once a day for 52 weeks
Study: NCT03226522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00362024
Drug: MK0952
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00362024
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712476
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: mannitol alone is compared with placebo
Study: NCT05470972
Drug: Ethanol Injection
Normalized name: ethanol Injection
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The AEST procedure was performed as follows: vaginal walls were cleansed using vaginal povidone-iodine, a 17 gauge, 30-cm length needle was inserted through the posterior vaginal fornix into the pouch of Douglas, and the cyst was aspirated till complete disappearance of the cyst on the ultrasound scanner. The collected cystic fluid was collected into a plastic tube without an anticoagulant. The needle was maintained in its place, the syringe was removed and the cyst was flushed with saline solution until obtaining a clear liquid. Then, 96% ethanol was injected as 60% of the volume of the aspirated fluid to guard against over distension or rupture of the cyst and/or ethanol diffusion into the pelvis. The collected fluid was divided into three sterile tubes for cytological and bacteriological examinations and the study investigations. Patients were allowed to be completely recovered and were discharged home.
Study: NCT00807196
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
Study: NCT03154645
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: non-steroidal anti-inflammatory drug